Eradication of Helicobacter pylori infection

Kaohsiung Journal of Medical Sciences

Volumn 30, Issue 4, 2014, Pages 167-172

  Wu, Tzung Shiun ^a   Hu, Huang Ming ^a   Kuo, Fu Chen ^b   Kuo, Chao Hung ^a,c  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b I SHOU UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Bismuth containing quadruple therapy; Helicobacter pylori infection; Rescue therapy; Standard triple therapy

Indexed keywords

ANTIBIOTIC AGENT; BISMUTH; CLARITHROMYCIN; FURAZOLIDONE; LEVOFLOXACIN; QUINOLONE; RIFABUTIN;

ANTIBIOTIC RESISTANCE; DISEASE ERADICATION; GASTROINTESTINAL DISEASE; GENOTYPE; HELICOBACTER INFECTION; HUMAN; NONHUMAN; PATIENT COMPLIANCE; REVIEW; TREATMENT FAILURE; HELICOBACTER INFECTIONS;

DISEASE ERADICATION; HELICOBACTER INFECTIONS; HUMANS;

EID: 84896487902     PISSN: 1607551X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.kjms.2013.11.003     Document Type: Review

References (58)

1. A. Kandulski, M. Selgrad, and P. Malfertheiner Helicobacter pylori infection: a clinical overview Dig Liver Dis 40 2008 619 626
2. P. Malfertheiner, F. Megraud, C.A. O'Morain, J. Atherton, A.T. Axon, and F. Bazzoli et al. Management of Helicobacter pylori infection - the Maastricht IV/Florence Consensus Report Gut 61 2012 646 664
3. H.G. Park, M.K. Jung, J.T. Jung, J.G. Kwon, E.Y. Kim, and H.E. Seo et al. Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naive patients Aliment Pharmacol Ther 35 2012 56 65
4. C.S. Qua, J. Manikam, and K.L. Goh Efficacy of 1-week proton pump inhibitor triple therapy as first-line Helicobacter pylori eradication regime in Asian patients: is it still effective 10 years on? J Dig Dis 11 2010 244 248
5. M. Sasaki, N. Ogasawara, K. Utsumi, N. Kawamura, T. Kamiya, and H. Kataoka et al. Changes in 12-year first-line eradication rate of Helicobacter pylori based on triple therapy with proton pump inhibitor, amoxicillin and clarithromycin J Clin Biochem Nutr 47 2010 53 58
6. S.K. Chuah, F.W. Tsay, P.I. Hsu, and D.C. Wu A new look at anti-Helicobacter pylori therapy World J Gastroenterol 17 2011 3971 3975
7. D.Y. Graham, and L. Fischbach Helicobacter pylori treatment in the era of increasing antibiotic resistance Gut 59 2010 1143 1153
8. J.P. Gisbert, R. Pajares, and J.M. Pajares Evolution of Helicobacter pylori therapy from a meta-analytical perspective Helicobacter 12 Suppl 2 2007 50 58
9. F. Megraud H pylori antibiotic resistance: prevalence, importance, and advances in testing Gut 53 2004 1374 1384
10. E. Rimbara, L.A. Fischbach, and D.Y. Graham Optimal therapy for Helicobacter pylori infections Nat Rev Gastroenterol Hepatol 8 2011 79 88
11. V. De Francesco, F. Giorgio, C. Hassan, G. Manes, L. Vannella, and C. Panella et al. Worldwide H. pylori antibiotic resistance: a systematic review J Gastrointestin Liver Dis 19 2010 409 414
12. T. Kita, Y. Tanigawara, N. Aoyama, T. Hohda, Y. Saijoh, and F. Komada et al. CYP2C19 genotype-related effect of omeprazole on intragastric pH and antimicrobial stability Pharm Res 18 2001 615 621
13. F.C. Cheng, S.K. Lam, and G.B. Ong Maximum acid output to graded doses of pentagastrin and its relation to parietal cell mass in Chinese patients with duodenal ulcer Gut 18 1977 827 832
14. C.H. Kuo, S.S. Wang, W.H. Hsu, F.C. Kuo, B.C. Weng, and C.J. Li et al. Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy Helicobacter 15 2010 265 272
15. J.C. Yang, H.L. Wang, H.D. Chern, C.T. Shun, B.R. Lin, and C.J. Lin et al. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication Pharmacotherapy 31 2011 227 238
16. X. Pan, Y. Li, Y. Qiu, Q. Tang, B. Qian, and L. Yao et al. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults Clin Ther 32 2010 2003 2011
17. J.H. Lee, H.Y. Jung, K.D. Choi, H.J. Song, G.H. Lee, and J.H. Kim The influence of CYP2C19 polymorphism on eradication of Helicobacter pylori: a prospective randomized study of lansoprazole and rabeprazole Gut Liver 4 2010 201 206
18. K.M. Fock, P. Katelaris, K. Sugano, T.L. Ang, R. Hunt, and N.J. Talley et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection J Gastroenterol Hepatol 24 2009 1587 1600
19. Y. Gumurdulu, E. Serin, B. Ozer, F. Kayaselcuk, K. Ozsahin, and A.M. Cosar et al. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey World J Gastroenterol 10 2004 668 671
20. D.Y. Graham, H. Lu, and Y. Yamaoka Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond Drugs 68 2008 725 736
21. E.R. Greenberg, G.L. Anderson, D.R. Morgan, J. Torres, W.D. Chey, and L.E. Bravo et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial Lancet 378 2011 507 514
22. T.J. Borody, P. Andrews, G. Fracchia, S. Brandl, N.P. Shortis, and H. Bae Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori Gut 37 1995 477 481
23. C.H. Kuo, F.C. Kuo, H.M. Hu, C.J. Liu, S.S. Wang, and Y.H. Chen et al. The optimal first-line therapy of Helicobacter pylori infection in year 2012 Gastroenterol Res Pract 2012 2012 168361
24. C.H. Kuo, P.I. Hsu, F.C. Kuo, S.S. Wang, H.M. Hu, and C.J. Liu et al. Comparison of 10-day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: a randomized controlled trial J Antimicrob Chemother 68 2013 222 228
25. C. O'Morain, T. Borody, A. Farley, W.A. De Boer, C. Dallaire, and R. Schuman et al. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study Aliment Pharmacol Ther 17 2003 415 420
26. L. Laine, R. Hunt, H. El-Zimaity, B. Nguyen, M. Osato, and J. Spenard Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial Am J Gastroenterol 98 2003 562 567
27. P. Malfertheiner, F. Bazzoli, J.C. Delchier, K. Celinski, M. Giguere, and M. Riviere et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial Lancet 377 2011 905 913
28. D. Vaira, A. Zullo, N. Vakil, L. Gatta, C. Ricci, and F. Perna et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial Ann Intern Med 146 2007 556 563
29. N. Sirimontaporn, D. Thong-Ngam, S. Tumwasorn, and V. Mahachai Ten-day sequential therapy of Helicobacter pylori infection in Thailand Am J Gastroenterol 105 2010 1071 1075
30. J.M. Liou, C.C. Chen, M.J. Chen, C.Y. Chang, Y.J. Fang, and J.Y. Lee et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial Lancet 381 2013 205 213
31. L. Gatta, N. Vakil, G. Leandro, F. Di Mario, and D. Vaira Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children Am J Gastroenterol 104 2009 3069 3080
32. F.W. Tsay, H.H. Tseng, P.I. Hsu, K.M. Wang, C.C. Lee, and S.N. Chang et al. Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan J Gastroenterol Hepatol 27 2012 498 503
33. J.P. Gisbert, X. Calvet, A. O'Connor, F. Megraud, and C.A. O'Morain Sequential therapy for Helicobacter pylori eradication: a critical review J Clin Gastroenterol 44 2010 313 325
34. D.C. Wu, P.I. Hsu, J.Y. Wu, A.R. Opekun, C.H. Kuo, and I.C. Wu et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection Clin Gastroenterol Hepatol 8 2010 36 41 e1
35. A.S. Essa, J.R. Kramer, D.Y. Graham, and G. Treiber Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication Helicobacter 14 2009 109 118
36. P.I. Hsu, D.C. Wu, J.Y. Wu, and D.Y. Graham Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days Helicobacter 16 2011 139 145
37. S.K. Chuah, W.C. Tai, P.I. Hsu, D.C. Wu, K.L. Wu, and C.M. Kuo et al. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment - a pilot study Helicobacter 17 2012 374 381
38. M. Berning, S. Krasz, and S. Miehlke Should quinolones come first in Helicobacter pylori therapy? Therap Adv Gastroenterol 4 2011 103 114
39. J. Molina-Infante, B. Perez-Gallardo, M. Fernandez-Bermejo, M. Hernandez-Alonso, G. Vinagre, and C. Duenas et al. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication Aliment Pharmacol Ther 31 2010 1077 1084
40. M. Romano, A. Cuomo, A.G. Gravina, A. Miranda, M.R. Iovene, and A. Tiso et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial Gut 59 2010 1465 1470
41. G. Cammarota, A. Martino, G. Pirozzi, R. Cianci, G. Branca, and E.C. Nista et al. High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection Aliment Pharmacol Ther 19 2004 789 795
42. L.M. Best, D.J. Haldane, and G.S. Bezanson Veldhuyzen van Zanten SJ. Helicobacter pylori: primary susceptibility to clarithromycin in vitro in Nova Scotia Can J Gastroenterol 11 1997 298 300
43. J. Cabrita, M. Oleastro, R. Matos, A. Manhente, J. Cabral, and R. Barros et al. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999) J Antimicrob Chemother 46 2000 1029 1031
44. D.C. Wu, P.I. Hsu, H.H. Tseng, F.W. Tsay, K.H. Lai, and C.H. Kuo et al. Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies Medicine (Baltimore) 90 2011 180 185
45. J.P. Gisbert "Rescue" regimens after Helicobacter pylori treatment failure World J Gastroenterol 14 2008 5385 5402
46. M. Hojo, H. Miwa, A. Nagahara, and N. Sato Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection Scand J Gastroenterol 36 2001 690 700
47. J.P. Gisbert, and F. Morena Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure Aliment Pharmacol Ther 23 2006 35 44
48. C.H. Kuo, H.M. Hu, F.C. Kuo, P.I. Hsu, A. Chen, and F.J. Yu et al. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial J Antimicrob Chemother 63 2009 1017 1024
49. W.M. Wong, Q. Gu, K.M. Chu, Y.K. Yee, F.M. Fung, and T.S. Tong et al. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection Aliment Pharmacol Ther 23 2006 421 427
50. R.J. Saad, P. Schoenfeld, H.M. Kim, and W.D. Chey Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis Am J Gastroenterol 101 2006 488 496
51. P.I. Hsu, D.C. Wu, A. Chen, N.J. Peng, H.H. Tseng, and F.W. Tsay et al. Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures Eur J Clin Invest 38 2008 404 409
52. A. O'Connor, J.P. Gisbert, D. McNamara, and C. O'Morain Treatment of Helicobacter pylori infection 2010 Helicobacter 15 Suppl 1 2010 46 52
53. V. Savarino, P. Zentilin, M. Pivari, G. Bisso, M. Raffaella Mele, and C. Bilardi et al. The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori Aliment Pharmacol Ther 14 2000 893 900
54. C. Schabereiter-Gurtner, A.M. Hirschl, B. Dragosics, P. Hufnagl, S. Puz, and Z. Kovach et al. Novel real-time PCR assay for detection of Helicobacter pylori infection and simultaneous clarithromycin susceptibility testing of stool and biopsy specimens J Clin Microbiol 42 2004 4512 4518
55. J.P. Gisbert, and X. Calvet Review article: rifabutin in the treatment of refractory Helicobacter pylori infection Aliment Pharmacol Ther 35 2012 209 221
56. J.P. Gisbert, X. Calvet, L. Bujanda, S. Marcos, J.L. Gisbert, and J.M. Pajares 'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures Helicobacter 8 2003 90 94
57. G. Apseloff Severe neutropenia among healthy volunteers given rifabutin in clinical trials Clin Pharmacol Ther 74 2003 591 593
58. G. Treiber, S. Ammon, P. Malfertheiner, and U. Klotz Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures Helicobacter 7 2002 225 231